Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RN7SK pseudogene 217 refers to a specific member of the RN7SK pseudogene family. These are nonfunctional genomic sequences derived from the ancestral 7SK small nuclear RNA (snRNA) gene. The canonical 7SK snRNA is an abundant, highly conserved noncoding RNA that regulates eukaryotic transcription by controlling the activity of positive transcription elongation factor b (P-TEFb), participating in cell growth, proliferation, differentiation, and certain disease states[2][3][1]. However, "RN7SKP217" is a pseudogene variant, meaning it does not produce a functional RNA or protein product and has no known role in cellular processes or disease. There are numerous RN7SK pseudogenes in the human genome, and most are not transcribed or functionally characterized. The functional 7SK snRNA acts as a scaffold for ribonucleoprotein complexes controlling transcription elongation and is relevant in neural differentiation, cancer, and viral infection[1][2][3]. Pseudogenes like RN7SKP217 are genomic elements lacking promoter activity or harboring disruptive mutations that prevent them from being transcribed or functional, though rare exceptions exist where pseudogenes gain regulatory or pathological significance. There is no evidence that RN7SKP217 is active or relevant in this way. RN7SKP217 should not be listed as a therapeutic target, biomarker, or functional receptor. If the intent was to refer to the functional 7SK small nuclear RNA (7SK snRNA), refer to "7SK small nuclear RNA (7SK snRNA)" or "RNA, 7SK" and not a pseudogene designation[2][3][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RN7SK pseudogene 217 (RN7SKP217).